[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019

Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 30, Issue 3 (8-2022) ::
Journal of Ilam University of Medical Sciences 2022, 30(3): 75-87 Back to browse issues page
Evaluation of the Relationship between Peroxisome Proliferator Receptors (PPARα, PPARγ, and PPARδ) Expression and Carcinoembryonic Antigen (CEA) in Patients with Colorectal Cancer
Musa Yaghoubizadeh1 , Leila Pishkar2 , Gholam Basati * 3
1- Dept of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2- Dept of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
3- Dept of Clinical Biochemistry, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran , gholam.basati@gmail.com
Abstract:   (810 Views)
Introduction: Studies have shown that an increase in carcinoembryonic antigen (CEA) is associated with the progression of colorectal cancer and is considered a sensitive diagnostic factor for CRC. Moreover, the role of peroxisome proliferators (PPARs) has recently been considered in colorectal cancer. This study aimed to investigate the relationship between the expression level of PPARs and CEA level in patients with colorectal cancer.
Material & Methods: In this study, a total of 100 samples of primary tumor tissue along with adjacent healthy tissue samples and serum samples of patients with colorectal cancer who underwent surgery were prepared from the tumor bank of Tehran Cancer Institute in Thran, Iran. The expression level of peroxisome proliferator receptors (PRARs) in tissue samples and CEA level in serum samples were measured, and the relationship between these markers was evaluated as well. The financial support for the study was provided by the Islamic Azad University (grant number 132655).
(Ethic code: 132655)
Findings: The results of this study showed a significant increase in the expression level of PPARs and serum CEA levels in patients with colorectal cancer (P<0.01). Although the level of these markers had a significant relationship with the progression and spread of disease in patients (P<0.01), no significant relationship was observed between the expression of PPARs and serum CEA in these patients (P>0.05).
Discussion & Conclusion: Based on the obtained results, the expression level of PPARs and the serum CEA level are associated with the progression and spread of the disease; however, there is no significant relationship between the expression level of PPARs and the serum CEA level in patients with colorectal cancer.
Keywords: Carcinoembryonic antigen, Colorectal cancer, Peroxisome proliferator receptors
Full-Text [PDF 1290 kb]   (315 Downloads)    
Type of Study: Research | Subject: clinical biochemistry
Received: 2021/10/11 | Accepted: 2021/12/27 | Published: 2022/08/6
1. Wan M, Wang Y, Zeng Z, Deng B, Zhu B. Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways. Biosci Rep 2020; 40: BSR20200265. doi: 10.1042/BSR20200265.
2. Siegel R, Miller K, Sauer A. Colorectal Cancer Statistics, 2020. Ca Cancer J Clin 2020;70:145–64. doi: 10.3322/caac.21601.
3. Ogunwobi O, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int J Mol Sci 2020; 21: 5311. doi:10.3390/ijms21155311.
4. Rahimi Pordanjani S, Baeradeh N, Lotfi MH, Pourmohammadi B. Epidemiology of colorectal cancer: incidence, mortality, survival rates and risk factors. Razi J Med Sci 2016;23:41-50.
5. Janbabaei G, Hedayatizadeh-Omran A, Alizadeh-Navaei R, Moradi S, Ahmadi A.H, Rashidi Alashti M, et al. An epidemiological study on patients with colorectal cancer admitted to one referral center in north of Iran from 2006 to 2015. WCRJ 2017; 4: e841. doi: 10.32113/wcrj_20173_841.
6. Yaghoubizadeh M, Pishkar L, Basati GH. Aberrant Expression of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer and Their Association with Cancer Progression and Prognosis. Gastrointest Tumors 2020; 7:11–20. doi: 10.1159/000503995.
7. Blank A, Roberts DE 2nd, Dawson H, Zlobec I, Lugli A. Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far from the Tree? Front Med (Lausanne) 2018; 5: 234. doi: 10.3389/fmed.2018.00234.
8. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Sur-gical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94: 982-99. doi: 10.1038/sj.bjc.6603033.
9. Lee JH, Lee SW. The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches. Gastroenterol Res Pract 2017;:1-11. doi: 10.1155/2017/7521987.
10. Huang H, Zhang L, Chen DB, Yu XG, He XH, Liu M. Validation of Prognosis Value of Cumulative Prognostic Scores Based on Serum High-Density Lipoprotein Cholesterol and Albumin Levels in Patients with Colorectal Cancer. J Cancer 2019; 10: 35-42. doi: 10.7150/jca.26637.
11. Fattahi E, Somi MH, Ebrahimzade E, fakhrjo A, Naghashi Sh. Evaluation of Relationship between Serum Levels of Tumor Markers (CEA, CA19-9) with Diagnosis, Pathological Finding and Staging in Colorectal Carcinoma. Med J Tabriz Uni Med Sci Health Services 2012;33: 68-74.
12. Molnar L, Rahoty P, Bauer E, Ronay P, Besznyak I, Otto S. Correlation between the results of CEA test and the clinical stage of colorectal carcinoma. Acta chi Hung 2018; 27:27-34. doi: 10.5152/eurasianjmed.2018.17093.
13. Sener SF, Imperato JP, Chmiel J, Fremgen A, Sylvester J. The use of cancer registry data to study preoperative CEA level as an indicator of survival in colorectal cancer. Ca cancer J Clin 1989; 39: 50-70. doi: 10.3322/canjclin.39.1.50.
14. Björkman K, Jalkanen S, Salmi S, Mustonen H, Kaprio T, Kekki H. A prognostic model for colorectal cancer based on CEA and a 48-multiplex serum biomarker panel. Sci Rep 2021; 11: 4287. doi: 10.1038/s41598-020-80785-1.
15. Villa A, Parra R, Feitosa M, Camargo M, Machado V, Tirapelli D,et al. PPARG expression in colorectal cancer and its association with staging and clinical evolution. Acta Cir Bras 2020; 35: e202000708.doi:10.1590/s0102-865020200070000008.
16. Lakshmi S, Reddy A, Banno A, Reddy C. PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Res 2017;8252796. doi: 10.1155/2017/8252796.
17. BP Kota, THW Huang, BD Roufogalis. An overview on biologicalmechanisms of PPARs. Pharmacol Res 2005; 51: 85-94. doi: 10.1016/j.phrs.2004.07.012.
18. Xue J, Zhu W, Song J, Jiao Y, Luo J, Yu C, et al. Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway. Oncogene 2018; 37: 953–62. doi: 10.1038/onc.2017.401.
19. Pazienza V, Vinciguerra M, Mazzoccoli G. PPARs signaling and cancer in the gastrointestinal system. PPAR Res 2012; 2012: 560846. doi: 10.1155/2012/560846.
20. Chen SW, Chou CT, Chang CC, Li YJ, Chen ST, Lin IC, et al. HMGCS2 enhances invasion and metastasis via direct interaction with PPARα to activate Src signaling in colorectal cancer and oral cancer. Oncotarget 2017; 8: 22460–76. doi: 10.18632/oncotarget.13006.
21. Ammazzalorso A, De Lellis L, Florio R, Bruno I, De Filippis B, Fantacuzzi M, et al. Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines. Chem Biol Drug Des 2017; 90: 1029–35. doi: 10.1111/cbdd.13026.
22. Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, et al. Alteration of gene expression in normalappearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 2004; 15;64: 3694–700. doi: 10.1158/0008-5472.CAN-03-3264.
23. Yang K, Fan KH, Lamprecht SA, Edelmann W, Kopelovich L, Kucherlapati R, et al. Peroxisome proliferatoractivated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int J Cancer 2005; 116:495-9. doi: 10.1002/ijc.21018.
24. Sabatino L, Fucci A, Pancione M, Colantuoni V. PPARG epigenetic deregulation and its role in colorectal tumorigenesis. PPAR Res 2012; 687492. doi: 10.1155/2012/687492.
25. Aires V, Brassart B, Carlier A, Scagliarini A, Mandard S, Limagne E, et al. A role for peroxisome proliferatoractivated receptor gamma in resveratrol-induced colon cancer cell apoptosis. Mol Nutr Food Res 2014; 58: 1785–94. doi: 10.1002/mnfr.201300962.
26. Assumpção JA, Magalhães KG, Corrêa JR. Correction to: the role of pparγ and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation. Cancer Cell Int 2017; 17: 99. doi: 10.1186/s12935-017-0463-1.
27. Sabatino L, Pancione M, Votino C et al. Emerging role of the 𝛽-catenin-PPAR𝛾 axis in the pathogenesis of colorectal cancer. World J Gastroenterol 2014; 20: 7137–151. doi: 10.3748/wjg.v20.i23.7137
28. Milone MR, Pucci B, Colangelo T et al. Proteomic characterization of peroxisome proliferator-activated receptor-𝛾 (PPAR𝛾) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. Mol Oncol 2016; 10: 1344–362. doi: 10.1016/j.molonc.2016.07.006
29. Morinishi T, Tokuhara Y, Ohsaki H, Ibuki E, Kadota K. Activation and Expression of Peroxisome Proliferator-Activated Receptor Alpha Are Associated with Tumorigenesis in Colorectal Carcinoma. PPAR Res 2019; 3,2019:7486727. doi: //doi.org/10.1155/2019/7486727.
30. Poureghbali S, Monsef Esfahani A, Jafari M. Correlation of Serum HER2-NEU, CA15-3 and CEA in Breast Cancer Patents and TNM Staging. Stu Med Sci 2015; 26: 513-18.
31. Silanian Toosi M, Salehi MH, Saidi Saedi H. Clinical Evaluation of Serum CEA and CA15-3 in Patients with Breast Cancer. J Guilan Uni Med Sci 2006; 15: 7-14. doi: 10.1093/annonc/mds604.
32. Yang KM, Park IJ, Kim ChW, Roh SA, Cho DH, Kim JCH. The prognostic significance and treatment modality for elevated pre- and postoperative serum CEA in colorectal cancer patients. Ann Surg Treat Res 2016; 91:165-71. doi: 10.4174/astr.2016.91.4.165.
33. Ishizuka M, Sawada T, Okada T, Nagata T, Takagi K, Horie T, et al. Influence of Tumor Peroxisome Proliferator-Activated Receptor γ and δ Expression on Postoperative Mortality of Patients Undergoing Colorectal Cancer Surgery. J Inves Sur 2009; 22:105–11. doi: 10.1080/08941930802713084.
34. Bagheri M, Kamani F. Consideration Of Relation Between Cea Amount And Stage Of Colorectal Cancer In Patients Referred To Taleghani In 2005-2006. Ann Mlitary Health Sci Res 2007; 5; s 1227-231.
35. choi JS, min JS. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients. Yonsei Med J 1997; 38:1-7. doi: 10.3349/ymj.1997.38.1.1.
Send email to the article author

Add your comments about this article
Your username or Email:


Ethics code: Ethics Committee of Islamic Adzad University

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yaghoubizadeh M, Pishkar L, Basati G. Evaluation of the Relationship between Peroxisome Proliferator Receptors (PPARα, PPARγ, and PPARδ) Expression and Carcinoembryonic Antigen (CEA) in Patients with Colorectal Cancer. J. Ilam Uni. Med. Sci. 2022; 30 (3) :75-87
URL: http://sjimu.medilam.ac.ir/article-1-7309-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 30, Issue 3 (8-2022) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4642